New experimental therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07441980
Summary
This is an early-stage study to test the safety and find the right dose of an experimental cell therapy called CT1390B. It will enroll up to 18 adults whose acute myeloid leukemia has come back or hasn't responded to standard treatments. The main goal is to see if the treatment is safe and to look for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, China
Conditions
Explore the condition pages connected to this study.